Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25453017 | 0.81 | ALDH1A1 (0.34) | ALDH1A1KDM4EMAPT | |
| SCHEMBL25453013 | 0.81 | ALDH1A1 (0.34) | ALDH1A1KDM4EMAPT | |
| SCHEMBL12932707 | 0.80 | HTT (0.34) | ALDH1A1KDM4ELMNAHTT | |
| SCHEMBL27027500 | 0.79 | — | — | |
| SCHEMBL823889 | 0.79 | ALDH1A1 (0.38) | ALDH1A1KDM4EMAPTPAOXUSP2 | |
| SCHEMBL20314459 | 0.79 | — | — | |
| SCHEMBL4951889 | 0.78 | HRH3 (0.35) | ALDH1A1KDM4EHTT | |
| SCHEMBL14032178 | 0.78 | HRH3 (0.35) | ALDH1A1KDM4EHTT | |
| SCHEMBL13801830 | 0.76 | SMN1; SMN2 (0.39) | ALDH1A1KDM4EUSP2 | |
| SCHEMBL10192131 | 0.76 | HRH3 (0.42) | ALDH1A1KDM4EPAOXUSP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210155604-A1 | QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2021-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155604-A1 | QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF | EGFR, ERBB2, ERBB4 | ALDH1A1 2980/4885KDM4E 4077/4885MAPT 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.